Metabolism of Long-Acting Rilpivirine after Intramuscular Injection: HIV Prevention Trials Network Study 076 (HPTN 076)

Herana Kamal Seneviratne, Joseph Tillotson, Julie M. Lade, Linda Gail Bekker, Sue Li, Subash Pathak, Jessica Justman, Nyaradzo Mgodi, Shobha Swaminathan, Nirupama Sista, Jennifer Farrior, Paul Richardson, Craig W. Hendrix, Namandje N. Bumpus

Research output: Contribution to journalArticlepeer-review

Abstract

A long-acting injectable formulation of rilpivirine (RPV), a non-nucleoside reverse transcriptase inhibitor, is currently under investigation for use in human immunodeficiency virus (HIV) maintenance therapy. We previously characterized RPV metabolism after oral dosing and identified seven metabolites: four metabolites resulting from mono-or dioxygenation of the 2,6-dimethylphenyl ring itself or either of the two methyl groups located on that ring, one N-linked RPV glucuronide conjugate, and two O-linked RPV glucuronides produced via glucuronidation of mono-and dihydroxymethyl metabolites. However, as is true for most drugs, the metabolism of RPV after injection has yet to be reported. The phase II clinical trial HPTN 076 enrolled 136 HIV-uninfected women and investigated the safety and acceptability of long-acting injectable RPV for use in HIV pre-exposure prophylaxis. Through the analysis of plasma samples from 80 of these participants in the active product arm of the study, we were able to detect 2 metabolites after intramuscular injection of long-acting RPV, 2-hydroxymethyl-RPV, and RPV N-glucuronide. Of the total of 80 individuals, 72 participants exhibited detectable levels of 2-hydroxymethyl-RPV in plasma samples whereas RPV N-glucuronide was detectable in plasma samples of 78 participants. In addition, RPV N-glucuronide was detectable in rectal fluid, cervicovaginal fluid, and vaginal tissue. To investigate potential genetic variation in genes encoding enzymes relevant to RPV metabolism, we isolated genomic DNA and performed next-generation sequencing of CYP3A4, CYP3A5, UGT1A1 and UGT1A4. From these analyses, four missense variants were detected for CYP3A4 whereas one missense variant and one frameshift variant were detected for CYP3A5. A total of eight missense variants of UGT1A4 were detected, whereas two variants were detected for UGT1A1; however, these variants did not appear to account for the observed interindividual variability in metabolite levels. These findings provide insight into the metabolism of long-acting RPV and contribute to an overall understanding of metabolism after oral dosing versus injection. ClinicalTrials.gov Identifier: NCT02165202

Original languageEnglish (US)
Pages (from-to)173-183
Number of pages11
JournalAIDS research and human retroviruses
Volume37
Issue number3
DOIs
StatePublished - Mar 2021

Keywords

  • HIV prevention
  • Rilpivirine
  • intramuscular injection
  • long-acting
  • metabolism

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Metabolism of Long-Acting Rilpivirine after Intramuscular Injection: HIV Prevention Trials Network Study 076 (HPTN 076)'. Together they form a unique fingerprint.

Cite this